Boost your knowledge of applications and techniques in nanoscale characterisation
Postnova Analytics to host free 1-day seminar on advanced separation techniques.
Postnova Analytics has announced a 1-day seminar examining the latest advanced separation techniques for the characterisation of nanoparticles, polymers and proteins.
This free seminar, due to be held on 17 November 2016 at the company's new UK headquarters in Malvern, has been designed to advance the attendees' knowledge of applications and techniques in nanoscale characterisation. The meeting will be particularly useful to those using Field-Flow Fractionation (FFF), Size Exclusion Chromatography (SEC/GPC) and Light Scattering, as well as scientists interested in how these techniques may be useful in their research.
The seminar has attracted presentations from expert guest speakers including Professor Beppe Battaglia - 'Making polymersomes: Challenges and solutions'; Dr Heidi Goenaga-Infante - 'FFF hyphenations for the characterisation of nanomaterials: from size-based speciation to number concentration'; Professor Nicola Tirelli - 'Microfluidic-based preparation of PLGA nanoparticles; and Professor Éva Valsami-Jones - 'The importance of nanomaterial characterisation in their safety assessment'.
As well as these eminent guest speakers, there will be presentations from Postnova scientists, discussions on FFF applications with experts in the field and updates on the latest instrumentation and detectors.
Separation techniques covered by the seminar will include Flow FFF (AF4), Thermal FFF, Centrifugal FFF and SEC/GPC. Detection techniques discussed will include Multi-Angle and Dynamic Light Scattering (MALS/DLS), Refractive Index (RI), Viscometry, UV and ICP-MS.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.